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Abstract
More than 300 years ago, Antony van Leewenhoeck first described observing single-celled microorganisms, which he termed “animalcules,”
examining his saliva under a microscope. Although the idea of the coexistence of microorganisms in our body is not new, we have only recently
been able to investigate their ecological relationship to our body, with the development of high-throughput molecular techniques. The diverse
microorganism communities residing in our guts are established and maintained by complex interactions among microorganisms and their
host. Notably, their alteration has been implicated in influencing various diseases including neurological diseases. Alzheimer’s disease (AD) is
the most common cause of dementia characterized by a progressive decline in memory and thinking severe enough to interfere with daily life.
Despite the great progress in linking genetic risk factors with AD pathogenesis, treatments targeted at AD pathology and its modifiers have not
yet resulted in a disease-modifying therapy. There is mounting evidence that the gut microbiota interacts with AD pathogenesis by disrupting
neuroinflammation and metabolic homeostasis—the gut microbiota has gone from being the forgotten organ to a potential key player in the
AD pathology.
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The resident microorganisms in our body, including bacteria, viruses, archaea, and fungi, outnumber eukaryotic cells by as many
as ten to one and their collective genome is estimated at 150 times
larger than the human gene complement (1,2). However, because of
their remarkably small size—typically 0.5–5.0 µm, which is about
one tenth the size of eukaryotic cells, the microorganisms make up a
small portion of human body mass (0.3%–3% of total body mass).
Nevertheless, while establishing their colonies, these microbes perform various vital functions in our body, including releasing biochemical byproducts (3).
Microbes live and act in ecological communities. Each will communicate with other microbes by exchanging genetic and molecular
material, altering their collective behavior on a population-wide
level in response to surrounding species or stimuli (eg, temperature
and pH), and thereby remodeling the microbial composition of the
community (4–6). Furthermore, community building within the host
generates myriad products that modulate host physiology: extracellular enzymes, toxins, antimicrobial compounds, inflammatory

cytokines, and metabolites (7,8). Through dynamic microbe-microbe
and microbe-host interactions, the diverse community of microorganisms—collectively called microbiota or microbiome with their
genomic content—is not only established and maintained, but also
contributes beneficial or pathological influences to host health.
Despite the remarkable richness and diversity of human microbiota and their close physiological association to the human host,
their significance to human health and disease has long been overlooked due to inadequate analytical methods. With recent genetic
and metagenomic analysis tool development, more sophisticated
microbiota profiling techniques facilitated the characterization of
the structure of the microbiome and a better understanding of its
contribution to human health. Recent advances in microbiology
have characterized the functional interactions between microbiota
and host. This “forgotten organ” is now considered not only as a
key player in human homeostasis but also as direct/indirect causal
agent in influencing various diseases such as allergy, irritable bowel
syndrome, type 2 diabetes mellitus, obesity, and cancer (9).
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agents and pathogens into the brain driving excessive activation
of the brain’s innate cells (microglia). AD-related genetic risk factors may also contribute to the construction of a disease-associated
microbiota (eg, the presence of ApoE4 alleles accompany reduced
host-beneficial bacterial communities). Studies cited in this review
are mostly based on bacterial 16S rRNA gene sequencing techniques.
Therefore, from here, the terms “microbiota” or “microbiome” are
referring to the bacterial community. Studies involving microbiota
in other locations, such as nasal, skin, respiratory, are not discussed
due to the lack of published data. There may be bidirectional communications between gut microbiota and AD pathogenesis, but we
will focus on the contribution of gut microbiota to AD pathology
(ie, less known if the hallmarks of AD pathologies modulate the gut
microbiota communities). Finally, we will discuss current gaps in
knowledge as well as future directions of microbiota research in AD.

Gut Microbiome: Fundamentals and Functions
Most microorganisms in the gut are bacteria (18). In the general
public view, bacteria have been perceived as harmful to our health,
but modern bacteriology argues there exists a spectrum of “good”
to “bad” bacterial types depending on their influence on the host.
In fact, most gut microbiota are completely harmless (commensal)
or beneficial (symbiont), and relatively few types of bacteria pose
a modest degree of risk or disease (pathobiont) (19,20). Most of
the time, as in the case of the diverse gut bacteria, “harmful” bacteria are suppressed, and we live in harmony and balance with our
numerous gut bacteria (21,22). However, when the gut ecosystem
undergoes abnormal changes, the pathobionts become overpopulated, and the gut bacterial composition becomes unbalanced
(dysbiosis). Then, this imbalance may grow to create a diseaserelated microbiota community and coordinate inflammatory reactions or toxin release.
It is estimated that around 1,000 different bacterial species exist
in the human gut, and at least the same 10% of species are present
in every individual (1,23). The human microbiota composition is established in early development and is stably maintained over time in
healthy individuals. Eighty percent of our gut microbiota are made
up of the phyla Bacteroidetes and Firmicutes (24). Several other
phyla are represented: including the Actinobacteria, Fusobacteria,
and Verrucomicrobia. However, these phyla make up a small proportion of the gut microbiota. Classically pathogenic species, such
as Campylobacter jejuni, Salmonella enterica, Vibrio cholera and
Escherichia coli, and Bacteroides fragilis, exist in low prevalence
(~0.1%) (18,25). Firmicutes is the largest bacterial phylum in the gut
microbiota and includes 200 genera: Ruminococcus, Clostridium,
Eubacterium, Lactobacillus, Faecalibacterium, Roseburia, and
Mycoplasma. Most of these bacteria have a Gram-positive cell
wall structure with a thick peptidoglycan layer. On the other hand,
Bacteroidetes have a Gram-negative cell wall structure. These bacteria include the genera Bacteroides, Prevotella, and Xylanibacter
(26). Different from Gram-positive cell wall structure, Gramnegative cell structure consists of an extra outer membrane outside
the thin peptidoglycan layer, which makes bacteria less susceptible
to antibiotics. Also, the outer membrane of Gram-negative bacteria
contains lipopolysaccharide (LPS), which elicits a variety of immune responses in the host animal in which the bacteria reside. The
proportion of the two major phyla, Firmicutes and Bacteroidetes,
are inversely related. It has been reported that the Firmicutes to
Bacteroidetes ratio is correlated with obesity and other diseases, although it is debatable if the ratio is a good indicator associated with
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Recently, there has been immense excitement on the potential
contribution of the microbiota in our gastrointestinal (GI) system
to central nervous system (CNS) disease. The CNS and enteric nervous system of the GI tract are tightly connected by hormones,
neuromodulators, and neurotransmitters related to efferent/ afferent nerves including the vagus nerve. As most (>95%) of the
microbiota in our body are GI residents, these microbes are perfectly situated to react to and influence neuronal, humoral, metabolic, or immune signaling underlying the gut-brain relationship.
On the one hand, as an example, elevated levels of noradrenaline
in the gut lumen (eg, by stress) can influence gene expression or
abundance of some bacteria (10,11). On the other hand, mice
grown in a germ-free (GF) environment demonstrate exaggerated
stress responses and anxiety behaviors related to changes in the
hypothalamic-pituitary-adrenal axis (12). Similarly, disruption of
the maternal gut microbiome perturbs neurodevelopment of their
offspring, which show autism-like behaviors that can be rescued by
introducing the commensal bacteria species Lactobacillus reuteri
(13,14). These studies emphasize this bidirectional relationship and
support disruption of gut homeostasis as a potential risk factor in
psychiatric or neurological disorders.
Considering that gut microbiota has immune regulatory functions, it is not surprising that there have been attempts to find a
link between gut microbiota and diseases classically classified as
immune-mediated neurodegenerative disorders, such as multiple
sclerosis. For example, the induction of experimental autoimmune
encephalomyelitis, an animal model of multiple sclerosis, causes a
less severe phenotype in GF mice compared to that of conventionally
raised mice, perhaps by decreasing the pathogenic inflammatory response, such as IL-17A-producing T cell activation (15,16). Recently,
neuropathological relevance of the gut microbiota has been extended to progressive neurological disorders such as Parkinson’s
disease, characterized histologically by loss of dopaminergic neurons
in the substantia nigra and phenotypically by motor dysfunction
such as slowness of movement, tremor, and stiffness. Sampson and
colleagues used an α-synuclein over-expressing mouse model of
Parkinson’s disease to study the relationship between parkinsonian
motor dysfunction with gut microbiota. Notably, model mice treated
with an antibiotic drug cocktail or raised in GF conditions had less
severe motor deficits and brain pathology than untreated/normally
raised mice (17).
Alzheimer’s disease (AD) is the most common neurodegenerative
disorder and is primarily marked by global decline in cognitive
function, including in episodic memory, executive functioning, and
reasoning. Recently, there is growing interest in investigating the
role of the microbiota in AD pathogenesis (Table 1). However, most
studies investigating the contribution of the microbiota in AD pathogenesis are correlational. The microbiota-host dynamic is immensely
complex and is heavily influenced by various endogenous and exogenous factors. These have hindered investigation on precise biological causal pathways from specific microbes to AD pathology and
neurodegeneration.
In this review, we present an outline of the gut microbiota-brain
axis and summarize recent findings from both animals and humans
on the potential involvement of the gut microbiota in AD pathogenesis. We hypothesize that an altered/unhealthy gut microbial community (dysbiosis by several factors; eg, genetic, diet, stress, age) can
induce a peripheral inflammatory response that drives an altered
neuroinflammatory response in the brain (Figure 1). Over decades,
various factors may disrupt gut permeability and blood–brain barrier (BBB) integrity that accelerate entry of circulating inflammatory
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Table 1. Evidence Supporting the Association of Gut Microbiota with AD Pathogenesis
Subject

Method

Main findings

(62)
(61)
(98)
(97)
(60)
(69)
(68)
(63)

(64)
(70)
(99)
(96)

(65)

(78)

(67)
(72)
(77)

Note: AD = Alzheimer’s disease; APP = Amyloid precursor protein; APP/PS1 mice = Double transgenic mice expressing mutations in APP and PS1 genes;
Aβ = Amyloid beta; Ecc15 = Erwinia carotovora carotovora 15; GV-971 = a seaweed-derived oligosaccharide; i.p. = Intraperitoneal; 3xTG-AD mice = Triple
transgenic mice displaying both Aβ plaques and tau-containing neurofibrillary tangles; 5xFAD mice = Mice carrying five familial AD mutations in APP and PS1
transgenes; P301L = Transgenic mice expressing a mutation in human tau that causes a form of tau-related frontotemporal dementia that develop neurofibrillary
tangles; PS1 = Presenilin-1; SLAB51 = a probiotic formulation made of multiple live bacterial strains.

disease state because there is significant variability among healthy
individuals (23,27–29).
The commensal gut microbiota has many diverse roles in
regulating host function. Extensive research has focused on the
immunoregulatory effect of the commensal gut microbiota on both
the innate and adaptive immune systems (30). The commensal bacteria prevent the invasion of pathogenic bacteria or the overgrowth
of pathobionts in the residing bacteria community. Commensals
have been reported to release antibacterial peptides (eg, cathelicidin
and C-type lectin) or lactic acid to regulate the gut pH level (3,31).
Recent studies also support the idea that commensal gut microbiota contribute to maintaining the structure of the gut barrier. For
example, commensals express the small proline-rich protein 2A
(sprp 2A) and angiogenin3, which are associated with cell-to-cell
adhesion processes and vasculature development (25,32,33). The
immunoregulatory effects are not limited to local infection sites: diffusion of microbial products or inflammasomes may lead to systemic
distribution (34). The structural development of the immune system
is also dependent on commensal bacteria. For example, mice raised
in germ-free conditions have poorly developed intestinal lymphoid
tissues (35). Also, in a separate study, GF mice had impairments in

eliciting appropriate cytokine production accompanied by changes
in various immune features: CD4+ T helper cells, FoxP3+, Tregs, B
cells, Th17 cells, IgA, antimicrobial peptides, and MHC class II (16).
The diversity and composition of bacterial communities are important factors in maintaining immune homeostasis (34). For example, as pathogens invade tissues in the GI tract, they may activate
the IL-23 – IL-17 inflammatory cytokine axis to induce T-helper 17
(Th17) cells, resulting in tissue inflammation and destruction during
defense (36). However, an exaggerated immune response can induce
Th17 cell over-proliferation that may promote autoimmune diseases,
such as multiple sclerosis, arthritis, or inflammatory bowel disease.
The IL-23 – IL-17 axis including Th17 cell activation can be suppressed by IL-10 and IL-25 signaling. Some of these anti-inflammatory cytokines are produced by species-specific bacterial signals (eg,
polysaccharide A from B. fragilis), highlighting the importance of a
diverse bacterial community in immune homeostasis (37).
Another critical function of the gut microbiota is assisting nutrient metabolic processes. Indigestible complex carbohydrates, such
as cellulose fibers, are broken down into oligosaccharides by the bacteria in the GI tract. These are then converted to short-chain fatty
acids (eg, butyrate, propionate, and acetate) that human cells can
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AD Human patients Specific microbial DNA qPCR Assay using fecal Escherichia/Shigella (related to proinflammatory)↑;
smaples.
Eubacterium rectale (related to anti-inflammatory)↓
AD Human patients 16S rRNA gene sequencing using fecal samples. Firmicutes↓; Bacteroidetes↑; Bifidobacterium↓
AD Human patients 16S rRNA sequencing using AD brain tissues Bacterial population in the brain ↑
AD Human patients Probiotic supplement
Kynurenine:tryptophan ratio↑
AD Human patients 16S rRNA gene sequencing using fecal samples. Bacteroides↓, Actinobacteria↑,
Ruminococcus↑, Lachnospiraceae↓
APP/PS1 mice
Life-long antibiotic treatment
Aβ plaque↓; plaque-localized glial reactivity ↓
APP/PS1 mice
Early postnatal antibiotic treatment
Aβ plaque↓; plaque-localized glial reactivity ↓
APP/PS1 mice
16S rRNA sequencing using fecal samples
SCFA ↓;
(8–12 mo of age)
Microbiota composition and diversity were perturbed
(eg, richness↑ at ~6 month; diversity↓ at ~12 month; Proteobacteria and
Verrucomicrobia ↑)
APP/PS1 mice
16S rRNA sequencing using fecal samples
Microbiota diversity↓; Spatial memory ↓;
(6 mo of age)
Odoribacter and Helicobacter↑ (at the genus)
APP/PS1 mice
Raising subjects in germ-free condition
Brain Aβ↓
(8 mo of age)
APP/PS1 mice
16S rRNA sequencing using fecal samples
Firmicutes: Bacteroidetes ratio↑ with age;
(3–24 mo of age)
Proteobacteria↑ (genus Shutterella↑); Erysipelotrichaceae↑
Aβ deposition↓ Cognitive decline↓
3xTG-AD mice
Oral treatment with SLAB51 probiotic
formulation at 8 wk for 4 mo.
(Behavioral test at 24-mo-old of age)
5xFAD mice
16S rRNA sequencing using fecal samples
Locomotion (=); food consumption (=);
(6–18 wk of age)
Aβ was found in the gut; trypsin ↓;
Firmicutes: Bacteroidetes ratio↑; Clostridium leptum ↑
5xFAD mice
GV-971 and Antibiotic treatment;
Firmicutes: Bacteroidetes ratio↑;
Co-housing;
Infiltrating Th1 cells & microglia activity ↑;
Microglia activity ↓ with antibiotic drugs & GV-971
P301L mice
16S rRNA sequencing using fecal samples
Firmicutes: Bacteroidetes ratio ↓;
(1,3,6, and 10 mo of age)
Rat
Helicobacter pylori filtrate i.p. injection
Aβ↑; Spatial memory ↓
Drosophila
Oral infection with Ecc15
Vacuolar degeneration ↑;
expressing Aβ42
Immune hemocyte in the brain ↑

Reference
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AD: Background and Key Risk Factors
AD is characterized by two distinct neuropathological hallmarks:
extracellular deposition of amyloid plaques and intracellular neurofibrillary tangle accumulation (38). Amyloid plaques are mainly
composed of Aβ peptides that are derived from the single-pass
transmembrane amyloid precursor protein (APP) after its sequential
cleavage by β- and γ- secretases. Under normal conditions, after Aβ
is generated and released to the extracellular space, it is monomeric
and soluble with a half-life of hours. However, during aging and
in particularly those who go on to develop AD, Aβ aggregates into
different structures including oligomers, protofibrils, and fibrils that
have a β-sheet structure and are associated with local toxicity. As Aβ
deposits in amyloid plaques, cerebrospinal fluid Aβ 42 levels decrease
likely due to sequestration of Aβ in amyloid plaques (39,40). Aβ
deposits may disrupt synaptic and neuronal activity as well as cause
focal cell damage associated with microglial and astrocytic activation, thereby resulting in localized oxidative stress and mitochondrial dysfunction (38,41). Importantly, through unclear mechanisms,
Aβ deposition appears to drive further aggregation and spreading of
tau pathology.
Neurofibrillary tangles are the other histopathological hallmark of AD. Neurofibrillary tangles are composed of hyperphosphorylated, aggregated forms of the tau protein. Tau is present
predominantly in neurons and contributes to the formation and stabilization of microtubules. Its excessive phosphorylation over time
as well as other factors, leads to the detachment of tau from microtubules. In this state, it can aggregate, resulting in the formation of
filamentous neurofibrillary tangles inside neurons. Aggregated forms
of tau are associated with interference in synaptic communication as
well as neuronal death (42,43).
AD is classically divided into two categories. Early-onset familial
Alzheimer’s disease (FAD) is inherited in an autosomal dominant
fashion and manifests with cognitive decline beginning most commonly between age 30 and 60 depending on the gene mutation and
family. FAD is caused by mutations in one of 3 genes APP, PSEN1,
and PSEN2 genes (encoding amyloid precursor protein, presenilin
1, and presenilin 2, respectively). Most of the mutations result in
an increase in the relative level of more amyloidogenic species of
Aβ such as Aβ 42 and Aβ 43. Mutations in these genes account for less
than 1% of AD cases. Most AD cases are sporadic with relatively
late onset typically after age 65, known as late-onset Alzheimer’s
disease (LOAD). The largest known risk factors for LOAD are age
and genetic factors, though it is likely there are several environmental and other risks (44). The strongest genetic risk factor is the
apolipoprotein E (APOE) gene, which has 3 common variants denoted ε2, 3, and 4 (APOE2/3/4) (45,46). Compared to the common
ε3 variant, the presence of an APOE4 allele increases and APOE2
decreases AD risk. One copy of APOE4 increases a person’s risk
of developing the disease approximately 4-fold, and two copies of
APOE4 increase the risk approximately 12-fold relative to individuals who are APOE3/E3. One copy of APOE2 decreases risk by ~0.6
relative to individuals who are APOE3/E3 (47). APOE is the most

abundant apolipoprotein produced in the brain, mainly expressed
in astrocytes but also in microglia under inflammatory conditions.
Neurons produce little APOE but express receptors for ApoE, such
as LDLR and LRP1 (48).
The involvement of innate immunity in AD is supported by the
fact that other risk factors for LOAD associate with genes expressed
exclusively or at high levels in microglia (eg, TREM2, CD33, other)
(49,50). Also, a recent epigenomic analysis showed that AD genomewide association study (GWAS) loci are preferentially enriched in
enhancer sequences associated with innate immune processes (51).
Rare variants in the triggering receptor expressed on myeloid cells
2 (TREM2) increase the risk of developing AD by two- to threefold
(47). TREM2 is a cell-surface receptor that is expressed in mononuclear phagocytes and microglia in the brain. Several lipids and
lipid-associated ligands can activate TREM2. One such ligand is
APOE, but whether APOE represents an important TREM2 ligand
in vivo is not yet clear (52–54). Emerging evidence however suggests that APOE and TREM2 somehow influence microglial activation under different conditions but how this occurs is not yet clear.
Inflammatory responses mediated by the APOE-TREM2 pathway
will be key to understanding different aspects of the brain’s innate
immune response to AD pathology.
Whether innate immune activation in AD represents a
neuroprotective or neurotoxic function is currently not clear. In fact,
accumulating evidence argues that the innate immune response may
differentially affect AD pathogenesis depending on disease stage
(53). For example, microglial activation may be protective against
AD pathology in early stages characterized by Aβ pathology via
decreasing/clearing plaques and reducing neuritic dystrophy. On
the other hand, in later stages of AD pathology with abundant tau
pathology, a disease-associated microglial response may be deleterious by directly targeting injured neurons and by activating a
toxic astrocyte response. In mouse models with Aβ deposition, genetic activation of microglia via TREM2 signaling resulted in more
compact Aβ plaques and a reduction in plaque-associated dystrophic
neurites (55,56). In contrast, genetic ablation of APOE in a mouse
model of tauopathy reduced glial activation which was associated
with markedly decreased neurodegeneration (45). Despite progress
in identifying substantial genetic risk factors and their functional
link to neuroinflammation in AD pathology and progression, these
risk-factor genes do not completely explain the etiology of LOAD.
Specifically, inheriting these risk-factor genes does not definitely
predict the development of AD (ie, some people who carry one or
two APOE ɛ4 alleles never develop AD, and others can develop
AD without APOE ɛ4 alleles). This suggests that other factors are
involved that also disrupt the homeostatic orchestration of brain
immunity and metabolism.
Although a vast literature in the field has focused on the role
of CNS neuroinflammation and innate immunity in AD pathology,
there is mounting interest in the contribution of the peripheral immune system. Some studies have demonstrated the presence of bloodderived leukocytes (eg, lymphocytes, monocytes, and neutrophils) in
the brains of AD patients or animal models, suggesting possible involvement of the adaptive immunity in AD pathogenesis (57–59).
Baruch and colleagues showed that, in a mouse model with Aβ deposition (5xFAD), transient suppression of regulatory T (Treg) cells
using pharmacogenetic techniques led to a decrease in Aβ deposition
(59). In a separate study, genetic ablation of adaptive immune cells,
including T cells and B cells, in a mouse model with Aβ deposition,
significantly accelerated amyloid pathogenesis. Interestingly, in the
study, the authors observed that microglial morphology and brain
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absorb and use as an energy source (8). The gut bacteria are also
involved in lipid/protein metabolic processes and in synthesizing
vitamin K and vitamin B (25). In addition, recent studies have shown
that the gut microbial enzymes are involved in bile acid and polyphenol related processes. We will further discuss the role of the gut
microbiota in inflammation and metabolic homeostasis with AD
pathology later in this review.

1235

1236

Journals of Gerontology: BIOLOGICAL SCIENCES, 2020, Vol. 75, No. 7

Healthy Gut-Brain Axis

AD Gut-Brain Axis

Reactive
Microglia

Homeostatic
Microglia

b
a

Healthy
Neuron

Damaged or
Dead Neuron

Amyloid
plaque

Neurofibrillary
tangle

Experimental Evidences in the Contribution of
Gut Microbiota to AD
A limited, but growing, body of evidence from AD patients and
mouse models suggest that gut microbiota perturbation occurs with
AD and may influence certain aspects of AD pathology (Table 1).
Analysis of the gut microbiota profile in AD patients shown a stark
contrast with controls (60–62). For example, one study examining
AD patients showed decreased microbiota richness with a decrease
in the ratio of Firmicutes to Bacteroidetes (61). Another study reported an increase in the ratio of Firmicutes to Bacteroidetes accompanied by decreased Bacteroidetes and similar Firmicutes
abundance. Although these two studies support the interaction between gut microbiota and AD pathogenesis, the reason for the discrepancy in the changed composition of gut microbiota between two
studies is not clear. It might be due to the differences in methodology (eg, sample size, RNA sequencing area) and/or subjects (eg,
lifestyle, dietary habits). Notably, the increased ratio of Firmicutes:
Bacteroidetes has previously been observed in patients with type
2 diabetes or obesity, implying gut dysbiosis as a common thread
between pathology in other diseases (28). Proinflammatory related
bacteria including Escherichia/Shigella are increased in AD cases,
whereas anti-inflammatory related bacteria such as Eubacterium
rectale are decreased (62) suggesting a possible link between the gut
microbiome and neuroinflammation.
In a mouse model with Aβ deposition (APP/PS1), the microbiota
richness was increased early in life, while the diversity was decreased
with age (6–9 months) (63). In a separate study using the same
animal model, the diversity of microbiota was also decreased with
age (3–8 months) in the AD model, but not in wild-type mice (64).
Moreover, reduced diversity was correlated with greater Aβ deposition in the hippocampus and a decline in hippocampal-dependent
spatial memory. Notably, the authors highlighted that the reduction
of overall diversity was accompanied by elevations in certain bacterial populations, such as Odoribacter and Helicobacter. Another
study using a different Aβ deposition mouse model (5xFAD) reported an increased Firmicutes:Bacteroidetes ratio compared to
wild-type mice at 9 weeks of age (65). Interestingly, in this study, Aβ
peptide was found in gut tissue sections of 5xFAD mice, suggesting
the possibility that, in this model, Aβ may also directly influence
microbiota balance.
Altered microbiota composition is not always consistent among
animal and human studies (eg, increased Firmicutes:Bacteroidetes
ratio in 5xFAD vs decreased Firmicutes:Bacteroidetes ratio in AD
patients). Perhaps, this is due to substantial differences in normative
resident bacterial communities in each species, and/or divergence
in genetic backgrounds inducing AD-like pathology in transgenic
model systems (eg, differences in target promoter or differences in
inducing different stages of AD stages, that is, tauopathy) (66). Until
now, most animal-based studies in this field have focused on using
amyloid-induced model systems. However, a recent study examined

Brain parenchyma

Reactive
Astrocyte

Homeostatic
Astrocyte

Blood vessel

Blood vessel

Dysbiosis
Eubiosis

Figure 1. Hypothetical model illustrating impact of an altered gut microbiota
on AD pathogenesis. A balanced composition of gut microbiota with an
abundance of commensal bacteria is essential for healthy brain function (left).
In the lower half of each figure, blue color represents symbiont; black color
represents harmless commensal microbe; and red color represents pathobiont.
In the healthy status of the gut-brain axis, homeostatic astrocytes maintain their
extracellular environment and support the integrity of the brain blood barrier
protecting the CNS from exposure to peripheral agents/molecules. Pathogens
which do enter the CNS are scavenged by microglia. However, as pathobionts
become dominant in the gut (dysbiosis), excessive proinflammatory cytokines
and neurotoxic bacterial metabolites (eg, lipopolysaccharide) lead to disruption
of gut permeability and blood–brain barrier integrity. This then accelerates
entry of circulating inflammatory molecules and pathogens into the brain,
resulting in excessive activation of innate immunity. In turn, inappropriate
glial activity may worsen processes such as Aβ seeding and clearance or
local effects of Aβ (a), or exacerbate tau-mediated neurodegeneration in
later stages (b). AD = Alzheimer’s disease; CNS = Central nervous system.

the diversity and composition of the gut microbiota in a tauopathy
animal model (P301L). In the study, P301L mice had a decreased
Firmicutes:Bacteroidetes ratio with age compared to wild-type controls, the pattern of which is opposite to the finding from some
studies using amyloid-induced models (67). Despite this inconsistency, findings from these observational studies in AD-like animal
models and AD patients strongly support gut dysbiosis influencing
the pathogenesis of AD.
Several studies have attempted to demonstrate a causal link between microbiota perturbation on AD pathology using different
manipulation strategies (eg, treating with antibiotics, germ-free
conditions, rederiving normal microbiota, or introducing a specific pathogen). In one such study, Minter and colleagues treated an
amyloid mouse model (APP/PS1 mice) with a cocktail of antibiotics
during the early postnatal period. This resulted in long-term alterations of gut microbiota composition as well as reduced Aβ deposition in the hippocampus and in multiple cortical areas in APP/PS1
mice. The authors also observed that glial reactivity surrounding Aβ
deposition was reduced with the early postnatal antibiotic treatment
(68,69). Consistently, APP/PS1 mice raised in germ-free conditions
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cytokine profiles were altered in the adaptive immune system deficient mice with amyloid burden, suggesting that increased amyloid
burden is related to the abnormal microglial activity. Taken together,
these studies support a modulatory role for the peripheral adaptive
immune system in influencing the CNS innate immune system and
consequently AD pathogenesis (58). Given the intimate relationship
between the immune system and gut microbes, we might suspect
that the peripheral immune system may bridge the gut flora to AD
pathogenesis.
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As we discussed above, accumulating data support the potential
contribution of the gut microbiome to AD pathology, but there are
still many unanswered questions: what microbiological pathways
are actually involved in pathogenesis? How is the gut microbiome
able to modulate AD pathogenesis in the brain that is located distally and protected by the BBB? These are fundamentally challenging questions to address because genetic and environmental
risk factors can modulate various steps in microbiota–gut–brain
communication, and vice versa (Figure 2). Therefore, it is conceivable that such complex interplay may give rise to numerous putative pathways, for which several hypotheses have emerged over
the years.
Various lines of reasoning argue that the immune system is the
most likely bridge between the microbial community and AD pathogenesis. Microbes of the gut have considerable influence on the
peripheral immune system, making it an attractive putative bridge
to AD pathogenesis. Cell components and metabolites from an altered/unhealthy gut microbial community (dysbiosis caused by several factors; eg, genetic, diet, stress, age) can modulate innate and
adaptive immunity in the periphery and thereby influence CNS
neuroinflammatory activity (34). For example, pathogen-associated
substances in the GI tract may activate mast cells that travel to other
tissues and release inflammatory mediators such as cytokines and
chemokines, and reactive oxygen species (74). While this process
may protect against pathogens, it may also influence cells in the
CNS including astrocytes, microglia, and blood vessels in the brain.
Chronic mast cell activation can cause excessive neuroinflammation
and contribute to neurodegeneration. In addition, BBB permeability
is sensitive to proinflammatory mediators and regulation by innate immune cells including mast cells and microglia. Importantly,
increased BBB permeability may facilitate brain infiltration of immune cells or mediators and thereby accelerate neuroinflammation
(53,58,59,75). Postmortem analyses of AD brains have consistently
demonstrated BBB damage, and cases carrying the ApoE4 variant
have marked pericyte injury. In mice, ApoE deficiency causes BBB
leakage through a pathway connecting the lipoprotein receptor
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Figure 2. Schematic diagram of dysregulated gut-brain axis and its interaction
with AD pathology. Arrows indicate the direction of the effect. Arrows with
dashed lines indicate that no studies have explored this putative relationship
yet in the AD—gut microbiome field. Multiple risk factors (top), such as genetic
variants (eg, ApoE4 allele, which also can directly affect AD pathology and BBB
permeability) and environmental factors (eg, aging, alcohol consumption,
antibiotic drug treatment) lead to unbalanced gut microbiota composition
(dysbiosis). This gut dysbiosis contributes to AD-pathology progression by
generating inflammatory agents and bacterial metabolites that associate
with increased intestinal barrier and BBB dysfunction. Some cytokines (eg,
IL-17) and metabolites (eg, SCFA) can amplify the abundance of plasma T
helper type 1 (Th1) cells, which invade the brain parenchyma. These promote
neuroinflammation (ie, increase proinflammatory microglial abundance) and
contribute to AD pathogenesis: amyloid-β (Aβ) deposition and neurofibrillary
tangles (not investigated yet). Hypothetically the CNS-invading pathogens
or toxic bacterial metabolites may directly cause or facilitate AD pathology.
AD = Alzheimer’s disease; BBB = Blood–brain barrier; CNS = Central
nervous system; LPS = Lipopolysaccharide; SCFA = Short-chain fatty acids.
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showed reduced Aβ deposition in the cortex and hippocampus and
attenuated microglial activation compared to control mice. This result was reversed when the germ-free mice were recolonized with
microbiota from conventionally raised animals (70). Taken together, these animal findings using germ-free conditions or antibiotic
treatment support the notion that altering the gut microbiota in
AD animal models induced changes in neuroinflammation and Aβ
deposition.
At present, it remains unclear whether any single pathogen or
assembly of pathogens is specifically involved in the microbiota
influence on AD pathology. Some studies have tied cognitive decline and AD risk with exposure to common pathogens including
Cytomegalovirus, Herpes simplex virus type 1, Chlamydophila
pneumonia, and Helicobacter pylori (71). Others have even probed
whether a specific microbe can induce or accelerate AD pathology.
For example, recent observational studies suggest that H. pylori are
more abundant in AD patients or animal models of aspects of AD
than in controls. This has been tested experimentally: Wang and
colleagues injected rats with H. pylori filtrate, which exacerbated
Aβ 42 production in the hippocampus and spatial memory impairment (72). In addition, increased levels of H. pylori antibodies have
been detected both in plasma and cerebrospinal fluid of AD patients
(64,73).
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drive metabolic alterations in the host and could potentially influence AD pathogenesis. For example, the microbial-derived metabolite trimethylamine N-oxide (TMAO) can enter the brain and has
been connected with AD. A recent study has reported that individuals with AD dementia showed elevated TMAO levels in their CSF,
and interestingly the CSF TMAO was more associated with CSF
p-tau, but not Aβ levels (85). It has been reported that bacterially
produced bile acids, which are associated with cholesterol metabolism and clearance, are dysregulated in the serum of AD patients.
Bile acids are primarily synthesized in the liver, but secondary synthesis by bacteria was elevated in AD patients beyond that of controls (86). However, it is not clear how or whether these metabolites
directly influence AD pathology or neurodegeneration. Perhaps, this
secondary bile acid promotes BBB permeability or influences brain
metabolism. Elevated TMAO levels have been also implicated in diabetes and insulin resistance, which are known to be risk factors for
developing dementia (85,87).
Short-chain fatty acids (SCFAs) have well-characterized roles in
lipid/protein metabolic process and appear to have a protective role
against AD. This protection may occur by conferring energy to the
brain or regulating microglial maturation and function (8,88). Recent
studies have examined the gut microbiota composition of humans or
animal model systems carrying different ApoE alleles. Interestingly,
analysis of the gut microbiota of ApoE2, E3, or E4 carriers revealed
a lower abundance of the SCFA-producing Ruminococcaceae bacteria in ApoE4 carriers (89). SCFAs (ie, butyrate) play also plays an
important role in orchestrating the integrity of intestinal barrier. It is
possible that ApoE4 carriers lacking SCFA-producing bacteria face
greater vulnerability to intestinal barrier loss or intestinal permeability. In addition, recent studies have elucidated the role of SCFAs
in the modulation of the T cell fate through G-coupled protein receptor signaling (GPR41/GPR43) and epigenetic modifications,
suggesting another possibility that microbial-SCFAs influence AD
pathology through modulating peripheral inflammation (90,91).
The contribution of bacteria-derived amyloids to AD pathogenesis represents an interesting but still under-explored line of research.
It has been reported that Escherichia coli produce extracellular
amyloid fibers called curli, which also adopt a beta-sheet structure
(92,93). The relationship between curli and brain Aβ amyloidosis
and deposition is not clear. It is conceivable that amyloids like curli
may propagate to the CNS via peripheral nerves (eg, vagus nerve),
as recent studies demonstrated that α-synuclein protein, which also
forms an “amyloid” in Parkinson’s disease, travels along the vagus
nerve from the gut to the brain where it can seed CNS synuclein and
spread in the brain (94,95). Notably, a common pathway between
CsgA (a major structural subunit of curli), LPS, and Aβ is the activation of toll-like receptors that are expressed in microglial cells. Given
that the digestive track is a robust source of bacterial products,
chronic exposure to bacterial products could over-stimulate both the
peripheral and central nervous system. Increased inflammation by
other factors such as aging and stress could also potentially stimulate
permeability of both the GI tract and the BBB. Together, these may
facilitate greater access of inflammatory agents and pathogens to the
brain, altering the immunological balance (Figure 2).

Conclusion and Future Perspectives
In summary, the gut microbiota is actively involved in various aspects
of human physiology, and its malfunction is closely associated with
human disease including AD. Myriad factors maintain and modulate
a healthy gut microbiota throughout life, including aging processes,
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LRP1 with the CypA–nuclear factor-kB in pericytes. Notably, this
signaling is suppressed in ApoE3, but not ApoE4 expressing mice
(76).
It is known that peripheral infection (eg, respiratory infection by
Bordetella pertussis) can promote T cell infiltration and stimulate
neuroinflammation or Aβ deposition (71). Several recent studies have
extended this role for infiltrating peripheral immune cells to bridge
gut dysbiosis with Aβ-related pathogenesis. Wu and colleagues
showed that, using a Drosophila model system of AD, oral infection with a nonpathogenic enterobacteria (Ecc15) resulted in a significant increase of vacuolar degeneration compared to noninfected
controls. They further demonstrated that immune hemocyte recruitment into the brain may exacerbate this neurodegeneration (77).
In an elegant study, Wang and colleagues used the 5xFAD model
to report that shifts in gut microbiota track closely with changes
in Aβ-related pathogenesis and increases of proinflammatory types
of microglia. Intriguingly, these shifts were also tightly associated
with the number and pattern of infiltrating proinflammatory T
helper type 1 (Th1) cells in the brain (78). However, when the gut
microbiota of 5xFAD mice was perturbed with antibiotic drugs,
they exhibited fewer activated microglia and infiltrating Th1 cells.
Collectively, these findings support the hypothesis that gut dysbiosis
may stimulate the infiltration of peripheral immune cells into the
brain and thereby contribute to Aβ-related pathogenesis through
enhancing neuroinflammation (79).
A compromised BBB also opens the possibility for peripheral
pathogens from multiple different organs to enter directly into the
brain parenchyma and influence AD pathogenesis including Aβ formation. Tying Aβ directly to infectious disease, recent studies offer
a putative role for Aβ in protecting the CNS from invading microorganisms. In an animal model with Aβ deposition, viral infection
in the brain by Herpesviridae dramatically accelerated Aβ deposition which decreased viral spread (80). Similarly, it has been demonstrated that CNS-invading fungi Candida albicans can increase
Aβ deposition as well as attracting microglia to the site of infection,
thereby promoting antimicrobial activity (81). Additionally, bacterial products such as LPS, derived from the outer membrane of
Gram-negative bacteria, have been detected in brains of AD patients
and appear to amplify Aβ deposition. For example, intraperitoneal
LPS injection, but not saline injection, elevated Aβ 42 levels in the
brain of wild-type mice (82,83). Studies in AD cases or some animal
models of AD show that the abundance of the phylum Bacteroidetes,
which mostly consists of Gram-negative bacteria, increases alongside
pathological insult. Collectively, such studies suggest a potentially
interesting relationship tying neuroinflammation or AD pathology
with elevations in Bacteroidetes abundance and associated LPS. In
addition, a leaky gut (ie, increased intestinal permeability) may contribute to dysbiosis-related AD pathogenesis via increasing the translocation and systemic distribution of bacteria or bacterial-derived
endotoxins. Examination of gut communities in AD subjects reveal
reduced representation of the Bifidobacterium genus, which has a
well-supported role in maintaining gut mucosal barrier properties.
At present, studies directly examining the intestinal permeability in
AD patients or model systems of AD are lacking. Similarly, the field
would greatly benefit from studies assessing whether any correlation
exists between intestinal permeability and genetic risk factors for AD
including ApoE4 expression.
Further inspiration for putative pathways comes from the strong
correlation between AD and metabolic disorders (eg, 80% of AD
patients show impairment in glucose tolerance or have diabetes)
(84). Specifically, certain bacterial metabolites may modulate or
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dietary changes, and drug/alcohol consumption, among innumerable
others. Excessive, chronic, or acute shifts in critical factors may drive
a proinflammatory state to influence the CNS. Additionally, genetic
risk factors (eg, the presence of an ApoE4 allele) may contribute or
influence the presence of more disease-associated microbiota. Finally,
pathogenic agents may achieve direct access to the brain through a
compromised BBB.
Progress has been made in establishing a causal relationship
between alterations of the gut microbiota and AD pathogenesis.
However, current studies in animal model systems have largely focused on how alterations in the microbiota affect Aβ pathology. It
is hypothesized that the innate immunity of the brain has varying
influences and roles in AD pathogenesis depending on early versus
late phases; likewise, the relationship between AD pathogenesis
and the gut microbiota likely depends on disease stage. Therefore,
further systematic investigations are necessary to characterize the
contribution of gut microbiota to more diverse aspects of AD
pathology including tauopathy and neurodegeneration, which
highly impacts cognitive function (Figure 2). In addition, links between known AD key genetic risk factors (eg, APOE and TREM2)
and gut microbiota will extend our understanding on how gut
microbiota contribute to AD pathology. The gut microbiota likely
contributes to AD risk via influencing numerous avenues: aging,
diabetes, and sleep or circadian rhythm dysfunction. For this
reason, there will remain an immense number of putative pathways by which the microbiota might directly or indirectly affect
AD pathogenesis.
With the increased understanding of the relationship between
microbiome disruption and AD pathogenesis, shifting the gut microbiota balance towards a state of eubiosis, a healthy and balanced
state of gut microbiota composition, will be an interesting future
direction. A general concept in this field is “a diverse microbiota is
a healthy microbiota.” However, as we discussed above, this is not
always true. For example, some studies showed increased bacterial
richness in AD animal models or reduced amyloidosis alongside
microbiota perturbation with antibiotic drugs (Table 1). A challenging but clinically significant barrier is the need to reduce pathological bacteria and increase beneficial bacteria, and recent testing
in AD patients or animal models supports probiotics as a potential
therapy. With the advent of new therapeutic tools, harnessing and
manipulating the gut microbiota will represent an attractive and innovative strategy to counteract AD pathogenesis (96,97).
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